Key result
Astragalus polysaccharides therapy improved hematodynamics and cardiac ultra-structure, and reduced apoptosis and ROS formation in db/db diabetic mice hearts.
Why the study?
Oxidant stress contributes to diabetic cardiomyopathy, and this study aimed to determine whether the protective effect of Astragalus polysaccharides on diabetic cardiomyopathy is associated with an impact on oxidant stress.
Does Astragalus polysaccharides improve cardiac dysfunction and reduce oxidant stress in db/db diabetic mice?
Does Astragalus polysaccharides improve cardiac dysfunction and reduce oxidant stress in db/db diabetic mice?
Astragalus polysaccharides improve cardiac dysfunction and reduce oxidant stress in a mouse model of diabetic cardiomyopathy.
Supports cardioprotection in diabetic models; leaves open clinical translation.
OBJECTIVE: Oxidant stress plays an important role in the development of diabetic cardiomyopathy. Previously we reported that Astragalus polysaccharides (APS) rescued heart dysfunction and cardinal pathological abnormalities in diabetic mice. In the current study, we determined whether the effect of APS on diabetic cardiomyopathy was associated with its impact on oxidant stress. METHODS: Db/db diabetic mice were employed and administered with APS. The hematodynamics, cardiac ultra-structure, apoptosis, and ROS formation of myocardium were assessed. The cardiac protein expression of apoptosis target genes (Bax, Bcl-2, and caspase-3) and oxidation target genes (Gpx, SOD2, t/p-JNK, catalase, t/p-p38 MAPK, and t/p-ERK) were evaluated, respectively. RESULTS: APS therapy improved hematodynamics and cardinal ultra-structure with reduced apoptosis and ROS formation in db/db hearts. In addition, APS therapy inhibited the protein expression of apoptosis target genes (Bax, Bcl-2, and caspase-3) and regulated the protein expression of oxidation target genes (enhancing Gpx, SOD2, and catalase, while reducing t/p-JNK, t/p-ERK, and t/p-p38 MAPK) in db/db hearts. CONCLUSION: Our findings suggest that APS has benefits in diabetic cardiomyopathy, which may be partly associated with its impact on cardiac oxidant stress.
No takes yet. Share an insight, caveat, or question.
Chen et al. (2018) studied Diabetic cardiomyopathy. Astragalus polysaccharides (APS) was evaluated on Hematodynamics, cardiac ultra-structure, apoptosis, and ROS formation. Astragalus polysaccharides therapy improved hematodynamics and cardiac ultra-structure, and reduced apoptosis and ROS formation in db/db diabetic mice hearts.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: